TABLE 4.
Categorical interpretations for key antimicrobial agents, including changes, following recognition of a presumptive ESBL producer
| Hospital | Method | Drug and NCCLS interpretation reporteda (no. of changes) for the following test organism:
|
|||
|---|---|---|---|---|---|
| CT-6 (SHV-8) | CT-7 (AmpC) | CT-8 (SHV-4) | CT-9 (SHV-5) | ||
| A | Vitek with Expert system | Ceftazidime R, cefotaxime S (0) | Ceftazidime R, cefotaxime S (0) | Ceftazidime I→R, cefotaxime S→R (2) | Ceftazidime I→R, cefotaxime S→R (2) |
| B | Vitek with Expert system | Ceftazidime R, ceftriaxone S (0) | Ceftazidime R, ceftriaxone S (0) | Ceftazidime I→R, ceftriaxone S→R (2) | Ceftazidime I→R, ceftriaxone I→R (2) |
| C | Vitek | Ceftriaxone S, cefotaxime S, ceftizoxime S (0) | Ceftriaxone S, cefotaxime S, ceftizoxime S (0) | Ceftriaxone I→R, cefotaxime S→R, ceftizoxime S→R (3) | Ceftriaxone I, cefotaxime S, ceftizoxime S (0) |
| D | MicroScan | Ceftazidime R, aztreonam S→R (1) | Ceftazidime R, aztreonam S→R (1) | Ceftazidime R, aztreonam R (0) | Ceftazidime R, aztreonam R (0) |
| E | In-house broth microdilution | Ceftazidime R, cefotaxime S→R (1) | Ceftazidime R, cefotaxime I→R (1) | Ceftazidime R, cefotaxime S→R (1) | Ceftazidime R, cefotaxime S→R (1) |
| F | Disk diffusion | Ceftazidime R, cefotaxime S→R (1) | Ceftazidime R, cefotaxime R (0) | Ceftazidime R, cefotaxime S→R (1) | Ceftazidime R, cefotaxime R (0) |
| G | Disk diffusion | Ceftazidime R, ceftriaxone I→R, aztreonam I→R (2) | Ceftazidime R, ceftriaxone R, aztreonam I→R (1) | Ceftazidime R, ceftriaxone S→R, aztreonam R (1) | Ceftazidime R, ceftriaxone I→R, aztreonam R (1) |
a
S, susceptible; I, intermediate; R, resistant. Arrows indicate changes made to the reports.